Exogenus Therapeutics

Executive Summary

Exogenus Therapeutics is a Portuguese biotech company founded in 2015, focused on developing therapeutic solutions based on extracellular vesicles (EVs), particularly exosomes, and other nanoparticles. The company's lead candidate, Exo-101, is derived from umbilical cord blood cells and targets unmet needs in regenerative medicine and inflammatory diseases. With a preclinical stage, Exogenus is pioneering the use of EVs as a novel drug delivery modality, leveraging their natural ability to mediate intercellular communication and modulate immune responses. The technology holds promise for conditions such as wound healing, ischemia, and autoimmune disorders, where current treatments are limited. As a privately held, preclinical company, Exogenus faces significant development risks, including manufacturing scalability, regulatory pathway definition, and clinical validation. However, the growing interest in EV-based therapeutics and the company's unique platform position it for potential partnerships or financing. Upcoming catalysts include progression toward clinical trials, potential strategic collaborations, and fundraising to support IND-enabling studies. The company's success depends on demonstrating preclinical efficacy and safety, as well as navigating the complexities of EV characterization and production.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 Clinical Trial for Exo-10140% success
• Q1 2027Strategic Partnership or Licensing Deal with a Major Pharma30% success
• Q3 2026Series A Financing Round60% success